82152 Planegg-Martinsried, de
+1 (646) 378-2947
4SC to Highlight the Potential of its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium 'on Molecular Targets and Cancer Therapeutics'
'Our presence at EORTC underlines our commitment to developing oncology candidates that will offer an improved and targeted standard of care for cancer patients,' said Bernd Hentsch, Chief Development Officer, 4SC. 'We have focused our resources over the last three years in order to establish a pipeline of clinical and preclinical compounds targeting molecular pathways for various tumour types and hold the promise to provide more tailored treatment for patients.'
Poster Presentations by 4SC:
Poster Board: #076
Title: Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor
Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM,
Poster session on 'Genetics and epigenetics' Poster Presenter: Rüdiger Jankowsky, Anna Mais, Stefan W. Henning, Bernhard Hauns, Bernd Hentsch
Poster board: #078
Title: Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi)
Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM, Poster session on 'Genetics and epigenetics'
Poster Presenter: Bernhard Hauns, Anna Mais, Rüdiger Jankowsky, Bernd Hentsch, Wilhelm Haverkamp
Poster board: #135
Title: Preclinical Characterization of 4SC-202, a novel isotype specific HDAC inhibitor
Session date and time: 17 Nov 2010, 12:00 - 14:30 AM, Poster session on 'Molecular-targeted therapies-preclinical'
Poster Presenter: Stefan W. Henning, Robert Doblhofer, Hella Kohlhof, Rüdiger Jankowsky, Thomas Maier, Thomas Beckers, Matthias Schmidt and Bernd Hentsch
Poster Board: #037
Title: 4SC-207, a novel and highly potent anti-mitotic agent, active also on PgP expressing tumor cells resistant to other chemotherapeutic drugs, induces complete tumor stasis in in vivo tumor models
Session date and time: 19 Nov 2010, 8:00 - 9:30 AM, Poster session on 'Cell-cycle-interactive agents'
Poster Presenter: Aldo Ammendola, Rolf Krauss, Robert Doblhofer, Stefan Strobl, Svetlana Hamm, Matthias Schmidt, Petra Gimmnich, Klaus Pekari, Astrid Zimmermann, Bernd Hentsch
About Resminostat (4SC-201)
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor. HDAC inhibitors modify the DNA structure of tumour cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumour progression and induce tumour regression. Resminostat is currently in a Phase II study as a second line treatment for advanced hepatocellular carcinoma and as a third-line treatment in Hodgkin's lymphoma. In a completed Phase I trial in patients with various different cancer types, stable disease was achieved in over 50% of the patients, whilst the treatment was well tolerated and showed a positive, differentiating pharmacological profile to other drugs in this class.
This candidate is an oral, selective Class I histone-deacetylase (HDAC) inhibitor. In contrast to the further advanced pan- HDAC inhibitor resminostat it belongs to a different chemical class with a selective inhibitory effect on Class I HDAC enzymes. 4SC-202 enables a dual attack on malignant cancer cells as it exhibits a special anti-mitotic effect, which makes this candidate particularly suitable for the treatment of cancer types characterised by rapid tumour cell proliferation.
4SC-207 is a novel, orally available cell-cycle blocker (CCB) for the treatment of chemotherapy resistant tumours. This anti-mitotic compound inhibits the cell division of actively proliferating tumour cells. In preclinical testing, apoptosis was observed in dividing cancer cells only, rather than in non-proliferating cells. A prominent characteristic of 4SC-207 is its resistance breaking activity. 4SC-207 affects cancer cells which are already resistant to taxanes and alkaloids.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.